Bilastine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland) and HAS (France) recommended or restricted bilastine, while AWMSG (Wales) and CIPM (Spain) did not recommend it.
The file has been open for more than a decade: 14.8 years separate the first record, 8 Jun 2011 at HAS (France), from the most recent, 28 Apr 2026 at CIPM (Spain).
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), TLV (Sweden) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for bilastine, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 3 of 9 records date from 2023 or later.
Against its own class, bilastine is an outlier: 60% of its decisive outcomes were positive, where molecules sharing ATC class R06A average 81%.
HAS (France) was first to assess bilastine, on 8 Jun 2011; AOTMIT (Poland) did not open a file until 30 Apr 2025 — an unusually long tail of 13.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 9 dated records fall in 2011 alone.
2 of the 5 agencies here assessed bilastine more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 5 of the 18 agencies here have assessed bilastine.
The full ledger for bilastine reads 3 recommended, 2 not recommended, 2 other and 1 withdrawn, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 30 Apr 2025 | Bellix reimbursement recommendation | recommended | source |
| CIPM (Spain) | 26 Sep 2024 | Indicaciones terapéuticas autorizadas: Alivio sintomático de la rinoconjuntivitis alérgica y urticaria que cursen con sí… | excluded from SNS provision · art. 92 e | source |
| AWMSG (Wales) | 13 Oct 2011 | For the symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. | not endorsed (non-submission) | source |
| SMC (Scotland) | 8 Aug 2011 | Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria | not recommended | source |
| HAS (France) | 8 Jun 2011 | Listing (Transparency Committee) | ASMR V | source |
4 further decisions for bilastine, across 2 agencies, are not shown here. They include the most recent record on file, 28 Apr 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- desloratadine — same ATC class R06A — Antihistamines
- ketotifen — same ATC class R06A — Antihistamines
- rupatadine — same ATC class R06A — Antihistamines
- vutrisiran — also decided by CIPM in 2026Q2
- omalizumab — also decided by CIPM in 2026Q2
- azithromycin — also decided by CIPM in 2026Q2
Coverage: 9 decisions for bilastine from 5 agencies, 2011 to 2026. Data to 7 Sep 2026. ATC class R06A — Antihistamines. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.